Avicenna Medica

Avicenna Medica is a UK-based biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics for oncology and inflammatory diseases. The company's primary research centers on the ubiquitin-proteasome system, specifically targeting Ubiquitin-specific protease 7 (USP7) to restore tumor suppression and enhance immune responses. Its lead program, AM-101, is a potent and selective USP7 inhibitor currently in pre-clinical development for the treatment of various solid tumors. Avicenna Medica leverages its expertise in medicinal chemistry and structural biology to advance a pipeline of precision medicines aimed at high-unmet-need indications. Headquartered in Oxford, the company aims to translate complex biological insights into effective clinical candidates through a targeted drug discovery approach.